Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine

We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events. While colchicin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lems, Willem, Boers, Maarten, van Vollenhoven, Ronald F, Nurmohamed, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970260/
https://www.ncbi.nlm.nih.gov/pubmed/33727219
http://dx.doi.org/10.1136/rmdopen-2020-001560
_version_ 1783666400697516032
author Lems, Willem
Boers, Maarten
van Vollenhoven, Ronald F
Nurmohamed, Mike
author_facet Lems, Willem
Boers, Maarten
van Vollenhoven, Ronald F
Nurmohamed, Mike
author_sort Lems, Willem
collection PubMed
description We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events. While colchicine might be the first drug in the clinic, we expect that this is only the first in a future series of anti-inflammatory drugs used in secondary prevention of cardiovascular events.
format Online
Article
Text
id pubmed-7970260
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79702602021-04-01 Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine Lems, Willem Boers, Maarten van Vollenhoven, Ronald F Nurmohamed, Mike RMD Open Treatments We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events. While colchicine might be the first drug in the clinic, we expect that this is only the first in a future series of anti-inflammatory drugs used in secondary prevention of cardiovascular events. BMJ Publishing Group 2021-03-16 /pmc/articles/PMC7970260/ /pubmed/33727219 http://dx.doi.org/10.1136/rmdopen-2020-001560 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Treatments
Lems, Willem
Boers, Maarten
van Vollenhoven, Ronald F
Nurmohamed, Mike
Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
title Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
title_full Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
title_fullStr Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
title_full_unstemmed Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
title_short Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
title_sort antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
topic Treatments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970260/
https://www.ncbi.nlm.nih.gov/pubmed/33727219
http://dx.doi.org/10.1136/rmdopen-2020-001560
work_keys_str_mv AT lemswillem antirheumaticdrugsforcardiovasculardiseasepreventionthecaseforcolchicine
AT boersmaarten antirheumaticdrugsforcardiovasculardiseasepreventionthecaseforcolchicine
AT vanvollenhovenronaldf antirheumaticdrugsforcardiovasculardiseasepreventionthecaseforcolchicine
AT nurmohamedmike antirheumaticdrugsforcardiovasculardiseasepreventionthecaseforcolchicine

Ejemplares similares